Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Docetaxel + S63845 |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | triple-receptor negative breast cancer | not applicable | Docetaxel + S63845 | Preclinical - Pdx | Actionable | In a preclinical study, S63845 and Taxotere (docetaxel) demonstrated synergy in triple-negative breast cancer patient-derived xenograft models, resulting in enhanced tumor growth inhibition and overall survival compared to either agent alone (PMID: 28768804). | 28768804 |
PubMed Id | Reference Title | Details |
---|---|---|
(28768804) | Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. | Full reference... |